Zhaozhao Chen

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

BMSCs-AML cell interaction drives FLT3 inhibitor resistance through the NR2F2/COX-2/PGE2 Axis.

BMSCs-AML cell interaction drives FLT3 inhibitor resistance through the NR2F2/COX-2/PGE2 Axis.

Journal: Cellular signalling

Published: May 14, 2026

In vivo CAR cell therapy: from bench to bedside.

In vivo CAR cell therapy: from bench to bedside.

Journal: Journal of hematology & oncology

Published: August 03, 2025

Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature.

Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature.

Journal: Journal for immunotherapy of cancer

Published: May 28, 2025

Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.

Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.

Journal: Thrombosis research

Published: May 13, 2025

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma.

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma.

Journal: Lancet (London, England)

Published: March 19, 2025

mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.

mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.

Journal: British journal of haematology

Published: November 10, 2024

Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials.

Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials.

Journal: Trends in biotechnology

Published: May 04, 2024

Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy.

Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 26, 2024

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects.

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 20, 2023

Co-delivery of fucoxanthin and Twist siRNA using hydroxyethyl starch-cholesterol self-assembled polymer nanoparticles for triple-negative breast cancer synergistic therapy.

Co-delivery of fucoxanthin and Twist siRNA using hydroxyethyl starch-cholesterol self-assembled polymer nanoparticles for triple-negative breast cancer synergistic therapy.

Journal: Journal of advanced research

Published: December 01, 2023

The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.

The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.

Journal: Med (New York, N.Y.)

Published: November 04, 2023

Enhancing the Treatment of Uncontrolled Inflammation through the Targeted Delivery of TPCA-1-Loaded Nanoparticles.

Enhancing the Treatment of Uncontrolled Inflammation through the Targeted Delivery of TPCA-1-Loaded Nanoparticles.

Journal: Pharmaceutics

Published: July 25, 2023

Showing 1-12 of 14

Last Updated: 09/26/2026